Fibrogen announces topline results from lelantos-1 phase 3 clinical study of pamrevlumab in non-ambulatory patients with duchenne muscular dystrophy

San francisco, june 07, 2023 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced topline data from the phase 3 lelantos-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with duchenne muscular dystrophy (dmd) on background corticosteroids. the study did not meet the primary endpoint of performance of the upper limb 2.0 (pul 2.0) score at week 52 compared to baseline. pamrevlumab was generally safe and well tolerated and the majority of treatment emergent adverse events were mild or moderate.
FGEN Ratings Summary
FGEN Quant Ranking